查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1435104

Alpha1 抗胰蛋白酶缺乏症治疗药物市场：治疗方法、给药途径、通路 - 全球预测 2024-2030

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

α1-抗胰蛋白酶缺乏症治疗市场规模预计到2023年为30.2亿美元，2024年达到32.6亿美元，预计到2030年将达到55.7亿美元，复合年增长率为9.15%。

α-1抗胰蛋白酶缺乏症药物的全球市场

主要市场统计
基准年[2023] 30.2亿美元
预测年份 [2024] 32.6亿美元
预测年份 [2030] 55.7亿美元
复合年增长率（%） 9.15%
α1抗胰蛋白酶缺乏症治疗药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估α1-抗胰蛋白酶缺乏药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 Alpha-1 抗胰蛋白酶缺乏症治疗药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-α1抗胰蛋白酶缺乏症治疗药物市场的市场规模与预测是多少？

在 2-α1 抗胰蛋白酶缺乏治疗药物市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-α1抗胰蛋白酶缺乏症治疗药物市场的技术趋势和法律规范是什么？

4-α1抗胰蛋白酶缺乏症治疗药物市场主要供应商的市场占有率为何？

进入5-α1抗胰蛋白酶缺乏症药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中 α1-抗胰蛋白酶缺乏症的发生率不断增加
      • 提高早期诊断和预防保健的意识
    • 抑制因素
      • 研发成本高且缺乏熟练的专业人员
    • 机会
      • 新型 α-1 抗胰蛋白酶缺乏症治疗方法的最新研究
      • 增加投资以实现医疗基础设施现代化
    • 任务
      • α1-抗胰蛋白酶缺乏症诊断的局限性
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场（依治疗）

  • 强化治疗
  • 支气管扩张剂
  • 皮质类固醇
  • 氧气疗法

第七章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场：依给药途径

  • 吸入
  • 注射
  • 口服

第八章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场：按分销管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章北美和南美Alpha1抗胰蛋白酶缺乏症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区Alpha1抗胰蛋白酶缺乏症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的α1-抗胰蛋白酶缺乏症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abeona Therapeutics Inc
    • Alnylam Pharmaceuticals, Inc.
    • Apic Bio
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Cedars-Sinai Health System
    • Centessa Pharmaceuticals PLC
    • Chiesi Farmaceutici SpA
    • CSL Limited
    • Curaxys SL
    • Dicerna Pharmaceuticals, Inc
    • GlaxoSmithKline PLC
    • Grifols, SA
    • Inhibrx, Inc.
    • Intellia Therapeutics, Inc.
    • Kamada Ltd.
    • Krystal Biotech, Inc.
    • LFB Biomedicaments SA
    • Mereo Biopharma Group PLC
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • PH PHARMA CO. LTD
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-C002B1C99874

[198 Pages Report] The Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024, at a CAGR 9.15% to reach USD 5.57 billion by 2030.

Global Alpha 1 Antitrypsin Deficiency Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.02 billion
Estimated Year [2024] USD 3.26 billion
Forecast Year [2030] USD 5.57 billion
CAGR (%) 9.15%
Alpha 1 Antitrypsin Deficiency Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Augmentation Therapy
    • Bronchodilators
    • Corticosteroids
    • Oxygen Therapy
  • Route of Administration
    • Inhalation
    • Injection
    • Oral
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alpha 1 Antitrypsin Deficiency Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha 1 Antitrypsin Deficiency Treatment Market?

3. What are the technology trends and regulatory frameworks in the Alpha 1 Antitrypsin Deficiency Treatment Market?

4. What is the market share of the leading vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market?

5. Which modes and strategic moves are suitable for entering the Alpha 1 Antitrypsin Deficiency Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of alpha 1 antitrypsin deficiency among population
      • 5.1.1.2. Growing awareness about early diagnosis and preventive care
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and dearth of skilled professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research on new alpha 1 antitrypsin deficiency treatments
      • 5.1.3.2. Increasing investments to modernize healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Augmentation Therapy
  • 6.3. Bronchodilators
  • 6.4. Corticosteroids
  • 6.5. Oxygen Therapy

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Injection
  • 7.4. Oral

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
  • 8.3. Online

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abeona Therapeutics Inc
    • 13.1.2. Alnylam Pharmaceuticals, Inc.
    • 13.1.3. Apic Bio
    • 13.1.4. Arrowhead Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Baxter International Inc.
    • 13.1.7. Cedars-Sinai Health System
    • 13.1.8. Centessa Pharmaceuticals PLC
    • 13.1.9. Chiesi Farmaceutici S.p.A.
    • 13.1.10. CSL Limited
    • 13.1.11. Curaxys S.L.
    • 13.1.12. Dicerna Pharmaceuticals, Inc
    • 13.1.13. GlaxoSmithKline PLC
    • 13.1.14. Grifols, S.A.
    • 13.1.15. Inhibrx, Inc.
    • 13.1.16. Intellia Therapeutics, Inc.
    • 13.1.17. Kamada Ltd.
    • 13.1.18. Krystal Biotech, Inc.
    • 13.1.19. LFB Biomedicaments S.A.
    • 13.1.20. Mereo Biopharma Group PLC
    • 13.1.21. Novo Nordisk A/S
    • 13.1.22. Pfizer, Inc.
    • 13.1.23. PH PHARMA CO. LTD
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Vertex Pharmaceuticals Incorporated
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET DYNAMICS
  • FIGURE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 17. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 188. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET LICENSE & PRICING